• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The REMATCH trial: Left ventricular assist devices reduce mortality in heart failure [Classics Series]

byAndrew Cheung, MD MBA
July 13, 2016
in General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with end-stage heart failure on optimal medical therapy, treatment with a left ventricular assist device (LVAD) significantly reduced the risk of all-cause mortality when compared with medical therapy alone.

2. The difference in mortality was observed at 1 year, while no significant differences were observed at the 2-year mark.

Original Date of Publication: November 2001

Study Rundown: In patients with severe heart failure, cardiac transplantation has been shown to provide considerable benefit, though the supply of donor hearts is incredibly limited and has been approximated at about 3000 per year. As a result, much research has focused on mechanical means of improving myocardial function, and several such left ventricular assist devices (LVADs) have been developed through the National Institutes of Health artificial-heart program. Several devices have been previously approved by the Food and Drug Administration as bridging therapy to transplantation, though none have been studied as long-term alternatives to transplantation. The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial explored whether a specific type of LVAD, when used in the long-term, would reduce mortality in patients with end-stage heart failure who are not eligible for cardiac transplantation when compared with optimal medical therapy. In summary, this study found that treating end-stage heart failure patients with this LVAD significantly reduced the risk of mortality 1-year after randomization, though this difference was no longer seen at the 2-year mark.

Click to read the study in NEJM

In-Depth [randomized controlled trial]: This trial was conducted at 20 cardiac transplantation centres across the United States. A total of 129 patients were randomized to treatment with either LVAD or optimal medical therapy. Adults with chronic end-stage heart failure were eligible for the trial. End-stage heart failure was defined as New York Heart Association (NYHA) class IV sympoms for at least 90 days, left ventricular ejection fraction (LVEF) <25%, peak oxygen consumption <12 mL/kg/min or continued need for intravenous inotropes for symptomatic hypotension, or worsening renal function/pulmonary congestion. The inclusion criteria were subsequently broadened, though only 5 patients were included under these broader criteria. The primary endpoint was all-cause mortality.

The study was terminated when the predetermined threshold of 92 deaths was reached. The risk of mortality was significantly lower in the group that received LVAD when compared to those on medical therapy (RR 0.52; 95%CI 0.34-0.78). The Kaplan-Meier estimates of survival demonstrated significantly reduced mortality in the LVAD group at the 1-year mark (p=0.002), though this difference was not significant at the 2-year mark (p=0.09). Patients in the LVAD group were significantly more likely to experience a serious adverse event compared to those on medical therapy (RR 2.35; 95%CI 1.86-2.95), including nonneurologic bleeding, neurologic dysfunction, supraventicular arrhythmia, and peripheral embolic events.

RELATED REPORTS

Interatrial shunt device not effective in patients with symptomatic heart failure

Predicted long-term effects of dapagliflozin in heart failure suggest association with improved event-free survival

Hemodynamic-guided management of heart failure may reduce hospitalization rates

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: congestive heart failurerematch trial
Previous Post

Only low risk of HIV transmission among those well controlled on antiretroviral therapy

Next Post

President Obama reflects on the Affordable Care Act

RelatedReports

30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Predicted long-term effects of dapagliflozin in heart failure suggest association with improved event-free survival

November 8, 2021
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Hemodynamic-guided management of heart failure may reduce hospitalization rates

September 22, 2021
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Relative risk of heart failure from traditional risk factors is greater in younger than in older adults

April 23, 2021
Next Post
President Obama reflects on the Affordable Care Act

President Obama reflects on the Affordable Care Act

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Catheter ablation more effective than antiarrythmic escalation for ventricular tachycardia: The VANISH trial

Gender conformity influences use of laxatives and muscle-building products

Gender conformity influences use of laxatives and muscle-building products

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.